At a glance
ClinicalIndex Comparison RecordN/ACompleted· 3,599 enrolled
Drug / intervention
No Intervention +1 moreother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Observational Study of Patient Cohorts Who Previously Received Long-term Treatment With Pioglitazone or Placebo in Addition to Existing Antidiabetic Medications.
In Brief
An observational study evaluating No Intervention for Diabetes Mellitus, Type 2. Completed, enrolled 3,599 participants.
Detailed Summary
The purpose of this study was to investigate the mortality and macrovascular morbidity as well as the incidence of malignancies over time, in high-risk diabetic participants who previously received long-term treatment with either pioglitazone or placebo in combination with their usual medication for glycaemic management.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
Countries--
Collaborators--
Timeline
N/ACompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartNov 2004
Primary CompletionNov 2011
First PostedFeb 2016
TodayJul 2026
First PostedFeb 10, 2016
Enrollment StartNov 1, 2004
Primary CompletionNov 1, 2011
TodayJul 2, 2026
Enrollment to primary: 7 yearsPosted 10.4 years ago
Interventions
No Interventionother
Participants who previously received Pioglitazone in the PROactive study (NCT00174993).
No Interventionother
Participants who previously received pioglitazone-matching placebo in the PROactive study (NCT00174993).